Aridis Pharmaceuticals (ARDS) Competitors $0.0013 +0.00 (+550.00%) As of 09/11/2025 01:05 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock ARDS vs. SCPS, SMFL, VRPX, STAB, EVLO, CMRA, GNCAQ, GNCA, AMPE, and HSTOShould you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Scopus BioPharma (SCPS), Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), Statera Biopharma (STAB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Ampio Pharmaceuticals (AMPE), and Histogen (HSTO). These companies are all part of the "pharmaceutical products" industry. Aridis Pharmaceuticals vs. Its Competitors Scopus BioPharma Smart for Life Virpax Pharmaceuticals Statera Biopharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Ampio Pharmaceuticals Histogen Aridis Pharmaceuticals (NASDAQ:ARDS) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Which has preferable earnings and valuation, ARDS or SCPS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAridis PharmaceuticalsN/AN/A-$30.37MN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A Does the media refer more to ARDS or SCPS? In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Aridis Pharmaceuticals Neutral Scopus BioPharma Neutral Which has more volatility & risk, ARDS or SCPS? Aridis Pharmaceuticals has a beta of 39.09, suggesting that its stock price is 3,809% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Is ARDS or SCPS more profitable? Company Net Margins Return on Equity Return on Assets Aridis PharmaceuticalsN/A N/A N/A Scopus BioPharma N/A N/A N/A Do institutionals & insiders hold more shares of ARDS or SCPS? 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryAridis Pharmaceuticals beats Scopus BioPharma on 3 of the 4 factors compared between the two stocks. Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart ARDS vs. The Competition Export to ExcelMetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$69K$873.44M$5.82B$10.17BDividend YieldN/A4.84%5.69%4.60%P/E RatioN/A1.1474.6725.98Price / SalesN/A27.05454.5485.61Price / CashN/A19.5637.0859.91Price / BookN/A6.8012.186.31Net Income-$30.37M-$4.20M$3.29B$270.86M7 Day PerformanceN/A8.71%1.08%3.46%1 Month PerformanceN/A11.25%7.32%6.57%1 Year PerformanceN/A25.29%63.11%28.39% Aridis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDSAridis PharmaceuticalsN/A$0.00+550.0%N/AN/A$69KN/A0.0030Gap DownSCPSScopus BioPharmaN/A$0.00+33.3%N/AN/A$17KN/A0.009SMFLSmart for LifeN/A$0.00+100.0%N/A-99.9%$16K$11.11M0.00110Gap UpVRPXVirpax Pharmaceuticals0.1889 of 5 stars$0.01flatN/A-99.9%$14KN/A0.007STABStatera BiopharmaN/A$0.00+100.0%N/A+0.0%$11KN/A0.0020Gap DownHigh Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/A-97.8%$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070News CoverageAMPEAmpio PharmaceuticalsN/A$0.00-96.8%N/A+22.7%$3KN/A0.0020Gap DownHSTOHistogenN/A$0.00+66.7%N/A-99.9%$2K$19K0.0020Gap Up Related Companies and Tools Related Companies SCPS Alternatives SMFL Alternatives VRPX Alternatives STAB Alternatives EVLO Alternatives CMRA Alternatives GNCAQ Alternatives GNCA Alternatives AMPE Alternatives HSTO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDS) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARDS Stock Alerts